EUVIMEDEUVIMED entdecken
VergleichsstudieOpen Access · CC BY 4.0

Comparison of protection against mpox following mRNA or modified vaccinia Ankara vaccination in nonhuman primates

Eric M Mucker, Alec W Freyn, Sandra L Bixler, Deniz Cizmeci, Caroline Atyeo, Patricia L Earl, Harini Natarajan, Genesis Santos, Tiffany R Frey, Rafael H Levin, Anusha Meni, Guha A Arunkumar und 19 weitere

Cell · 2024-10 · 187 (20) · 5540-5553.e10

DOI: 10.1016/j.cell.2024.08.043 ↗

Kurz gefasst

Vergleichsstudie in der Zeitschrift Cell, 2024-10. Verfasst von Eric M Mucker und 30 weiteren Autor:innen. Beteiligte Einrichtung: Virology Division, United States Army Medical Research Institute of Infectious Diseases, Fort Detrick, MD, USA. Hauptthemen laut MEDLINE: Vaccinia virus, Antibodies, Viral, Vaccination. Die Arbeit wurde bisher 112-mal zitiert (Crossref) und nennt 61 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Division of Intramural Research, National Institute of Allergy and Infectious Diseases.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

In 2022, mpox virus (MPXV) spread worldwide, causing 99,581 mpox cases in 121 countries. Modified vaccinia Ankara (MVA) vaccine use reduced disease in at-risk populations but failed to deliver complete protection. Lag in manufacturing and distribution of MVA resulted in additional MPXV spread, with 12,000 reported cases in 2023 and an additional outbreak in Central Africa of clade I virus. These outbreaks highlight the threat of zoonotic spillover by Orthopoxviruses. mRNA-1769, an mRNA-lipid nanoparticle (LNP) vaccine expressing MPXV surface proteins, was tested in a lethal MPXV primate model. Similar to MVA, mRNA-1769 conferred protection against challenge and further mitigated symptoms and disease duration. Antibody profiling revealed a collaborative role between neutralizing and Fc-functional extracellular virion (EV)-specific antibodies in viral restriction and ospinophagocytic and cytotoxic antibody functions in protection against lesions. mRNA-1769 enhanced viral control and disease attenuation compared with MVA, highlighting the potential for mRNA vaccines to mitigate future pandemic threats.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Vaccinia virusAntibodies, ViralVaccinationAnimalsmRNA VaccinesMpox, MonkeypoxViral VaccinesAntibodies, NeutralizingNanoparticlesFemaleRNA, MessengerMacaca mulattaMacaca fascicularisLiposomes

Stichwörter der Autor:innen

MVAantibodychallengecorrelatemRNAmonkeypoxmpoxprimateserologyvaccine

Substanzen

Antibodies, ViralmRNA VaccinesViral VaccinesAntibodies, NeutralizingRNA, MessengerLipid NanoparticlesLiposomes

Autor:innen und Institutionen

  • Virology Division, United States Army Medical Research Institute of Infectious Diseases, Fort Detrick, MD, USA.
  • Moderna Inc., Cambridge, MA, USA.
  • Laboratory of Viral Diseases, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, MD, USA.
  • National Emerging Infectious Diseases Laboratories (NEIDL), Boston University, Boston, MA, USA; Department of Virology, Immunology, and Microbiology, Boston University School of Medicine, Boston, MA, USA; Department of…
  • Moderna Inc., Cambridge, MA, USA. Electronic address: galit.alter@modernatx.com.
  • Virology Division, United States Army Medical Research Institute of Infectious Diseases, Fort Detrick, MD, USA. Electronic address: jay.w.hooper.civ@health.mil.

Förderung

  • Division of Intramural Research
  • National Institute of Allergy and Infectious Diseases

Zitieren

APA

Mucker, E. M., Freyn, A. W., Bixler, S. L., Cizmeci, D., Atyeo, C., Earl, P. L., Natarajan, H., Santos, G., Frey, T. R., Levin, R. H., Meni, A., Arunkumar, G. A., Stadlbauer, D., Jorquera, P. A., Bennett, H., Johnson, J. C., Hardcastle, K., Americo, J. L., Cotter, C. A., …, & Hooper, J. W. (2024). Comparison of protection against mpox following mRNA or modified vaccinia Ankara vaccination in nonhuman primates. Cell, 187(20), 5540-5553.e10. https://doi.org/10.1016/j.cell.2024.08.043

Vancouver

Mucker EM, Freyn AW, Bixler SL, Cizmeci D, Atyeo C, Earl PL, et al. Comparison of protection against mpox following mRNA or modified vaccinia Ankara vaccination in nonhuman primates. Cell. 2024;187(20):5540-5553.e10. doi:10.1016/j.cell.2024.08.043

BibTeX
@article{Mucker2024,
  author = {Mucker, Eric M and Freyn, Alec W and Bixler, Sandra L and Cizmeci, Deniz and Atyeo, Caroline and Earl, Patricia L and Natarajan, Harini and Santos, Genesis and Frey, Tiffany R and Levin, Rafael H and Meni, Anusha and Arunkumar, Guha A and Stadlbauer, Daniel and Jorquera, Patricia A and Bennett, Hamilton and Johnson, Joshua C and Hardcastle, Kath and Americo, Jeffrey L and Cotter, Catherine A and Koehler, Jeff W and Davis, Christopher I and Shamblin, Joshua D and Ostrowski, Kristin and Raymond, Jo Lynne and Ricks, Keersten M and Carfi, Andrea and Yu, Wen-Han and Sullivan, Nancy J and Moss, Bernard and Alter, Galit and Hooper, Jay W},
  title = {Comparison of protection against mpox following mRNA or modified vaccinia Ankara vaccination in nonhuman primates},
  journal = {Cell},
  year = {2024},
  volume = {187},
  number = {20},
  pages = {5540--5553.e10},
  doi = {10.1016/j.cell.2024.08.043}
}
Kostenlos starten →